Jun 08, 2021 / 12:50PM GMT
Krishna Chaitanya Arikatla - Goldman Sachs Group, Inc., Research Division - Research Analyst
Good morning, good afternoon, everyone. My name is Krishna Chaitanya Arikatla or K.C. Arikatla, and I cover European mid-cap pharma and life sciences companies for Goldman Sachs. It's my pleasure to have Mike McClellan CFO of Almirall; and Pablo Divasson, Head of Investor Relations at Almirall with us today.
In terms of the format for the session, it would be pretty interactive with Q&A starting right away. If you have any questions, please input your questions on the interface that you have on the right side, and I'll do my best efforts to ask those questions to management.
Questions and Answers:
Krishna Chaitanya Arikatla - Goldman Sachs Group, Inc., Research Division - Research AnalystNow moving on to questions, Mike, on 2021 guidance, you've had a very strong Q1, with good performance across all the key growth drivers. How should we think about the guidance in that context? Do you think it's quite conservative? And how should we think about a